BD Pledges $19 Billion US Investment in Supply Chain Pact With Federal Government

Becton, Dickinson and Company (BD) has reached an agreement with the US government to expand domestic production of essential medical consumables, committing to invest $19 billion in the United States over several years in exchange for relief from future tariffs, the company announced on October 6.

BD, which describes itself as the nation's largest manufacturer of essential medical consumables, makes syringes, needles, infusion pumps and other hospital products. The company said the partnership aligns with the Trump administration's efforts to expand domestic manufacturing capacity for products critical to patient care and healthcare preparedness.

What BD committed to

According to the company's release, BD intends to:

• Invest $19 billion in the US over several years, a figure that includes capital, operational and supply chain investments.
• Direct $3 billion of that total toward manufacturing expansion at strategic production sites across the country.
• Expand end-to-end US production by approximately 5 billion essential medical consumables a year, raising its share of domestically supplied essential medical consumables to roughly 80%.
• Manufacture all BD needles used in the US domestically, using American-made steel.

BD's US manufacturing network includes sites in Columbus and Broken Bow, Nebraska; Canaan, Connecticut; Añasco, Puerto Rico; Sandy, Utah; El Paso, Texas; Covington, Georgia; and Sumter, South Carolina, the company said. It did not say how the $3 billion would be divided among them.

Tariff relief tied to milestones

In return, the agreement provides relief from future tariffs imposed under Section 232 of the Trade Expansion Act on covered BD products and inputs. The relief is "subject to the final scope and implementation of any future Section 232 actions and BD's achievement of agreed milestones," the release said. Neither the milestones nor the products covered were disclosed.

BD said it is not quantifying the financial impact of the agreement because "the final tariff rates, product scope and effective timing have not yet been determined." The company said it expects to provide more information once Section 232 tariffs are finalized.

The Commerce Department opened a Section 232 investigation into imports of personal protective equipment, medical equipment and devices on September 2, 2025, MedTech Dive reported at the time. The goods under review ranged from surgical masks and syringes to intravenous bags, pacemakers, blood glucose monitors, wheelchairs and hospital beds, and the probe was to consider whether tariffs or quotas were warranted on national security grounds. As of the BD announcement, MedTech Dive noted, no tariffs specific to medical devices had been announced.

Company statement

"The administration recognizes the importance of investing in a stronger, more secure healthcare supply chain, and BD is uniquely positioned to help bring that vision to life through our scale, innovation expertise and longstanding U.S. manufacturing footprint," BD chairman, CEO and president Tom Polen said in the release.

Polen described the agreement as reflecting "a shared commitment between the U.S. Government and BD to strengthening America's healthcare infrastructure, expanding U.S. manufacturing capacity and supporting reliable access to essential medical technologies."

BD noted its role in past public health responses, citing its development of the first disposable syringe and its delivery of more than two billion additional devices "during the recent pandemic."

The company's announcement did not name the government agencies that are party to the agreement or give a timetable for the new production capacity. BD said the release contains forward-looking statements about each party's commitments under the agreement.